Journal
TOXICOLOGY REPORTS
Volume 4, Issue -, Pages 172-180Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.toxrep.2017.03.003
Keywords
Taste disorder; Bortezomib; Sour taste; Chemotherapy; Adverse effect
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology (MEXT), Research, and the Promotion Plan for the Platform of Human Resource Development for Cancer [16821327]
- Grants-in-Aid for Scientific Research [16H07326] Funding Source: KAKEN
Ask authors/readers for more resources
Chemotherapy-induced taste disorder is one of the critical issues in cancer therapy. Bortezomib, a proteasome inhibitor, is a key agent in multiple myeloma therapy, but it induces a taste disorder. In this study, we investigated the characteristics of bortezomib-induced taste disorder and the underlying mechanism in mice. Among the five basic tastes, the sour taste sensitivity of mice was significantly increased by bortezomib administration. In bortezomib-administered mice, protein expression of PKD2L1 was increased. The increased sour taste sensitivity induced by bortezomib returned to the control level on cessation of its administration. These results suggest that an increase in protein expression of PKD2L1 enhances the sour taste sensitivity in bortezomib-administered mice, and this alteration is reversed on cessation of its administration. (C) 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available